Events /// Investor News /// Investment Case /// Resources
Bayer is committed to providing sustainable solutions that address humanity’s most fundamental needs for essential healthcare and nutritious food. The Bayer Investor Relations Team is dedicated to creating transparency, fostering dialogue, and delivering value to our stakeholders.
Investor Resources
Investor News
Share Price / Index
April 29, 2026
Not intended for U.S. and UK Media
China’s Center of Drug Evaluation accepts marketing authorization application for Bayer’s FXIa inhibitor in stroke prevention after a non-cardioembolic ischemic stroke or transient ischemic attack
April 24, 2026
Bayer CEO Bill Anderson at the Annual Stockholders’ Meeting:
“We see great progress, but the work isn’t complete yet”
April 16, 2026
Not intended for U.S. and UK Media
Phase III study results with Bayer’s FXIa inhibitor demonstrating substantial reduction in ischemic stroke with no increase in ISTH major bleeding versus placebo published in New England Journal of Medicine
Discover More
